Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00475956
Status:
COMPLETED
Last Update Posted:
2010-04-15
First Post:
2007-05-18
Brief Title:
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Phase I Open-Label Study To Assess the Safety Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib RECENTINAZD2171 20 30 or 45mg When Co-Administered With Daily Oral Doses of AZD0530 125mg or 175mg in Patients With Advanced Solid Tumours
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine if the maximum tolerated doses of AZD2171 in combination with AZD0530 in treating patients with advanced solid tumours are safe tolerable and efficacious
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EuDract 2006-003505-55 | None | None | None |